ANRO
Alto Neuroscience, Inc.Healthcare · $913M market cap
Verdict
We can't put a fair value on ANRO right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
0 of 5 clear the 10% bar. What are the Big Five?
Follow ANRO
Track it on your watchlist and see the full analysis. Free.
Create a free accountSuperinvestors
None of the investors we track holds ANRO right now. In Q2 2026, 1 sold out. Who we track
Moves in Q2 2026
Sold out: Polen Capital Management
About Alto Neuroscience, Inc.
Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder. Also in its portfolio is ALTO-300, a small molecule designed to function as both a melatonergic…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works